Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Assets (2020 - 2025)

Foghorn Therapeutics has reported Assets over the past 6 years, most recently at $198.1 million for Q4 2025.

  • Quarterly results put Assets at $198.1 million for Q4 2025, down 30.24% from a year ago — trailing twelve months through Dec 2025 was $198.1 million (down 30.24% YoY), and the annual figure for FY2025 was $198.1 million, down 30.24%.
  • Assets for Q4 2025 was $198.1 million at Foghorn Therapeutics, down from $205.0 million in the prior quarter.
  • Over the last five years, Assets for FHTX hit a ceiling of $519.8 million in Q4 2021 and a floor of $186.1 million in Q3 2021.
  • Median Assets over the past 5 years was $297.1 million (2023), compared with a mean of $315.2 million.
  • Biggest five-year swings in Assets: soared 133.21% in 2022 and later tumbled 33.53% in 2025.
  • Foghorn Therapeutics' Assets stood at $519.8 million in 2021, then decreased by 22.1% to $404.9 million in 2022, then dropped by 29.38% to $285.9 million in 2023, then fell by 0.68% to $284.0 million in 2024, then crashed by 30.24% to $198.1 million in 2025.
  • The last three reported values for Assets were $198.1 million (Q4 2025), $205.0 million (Q3 2025), and $226.2 million (Q2 2025) per Business Quant data.